Jim Simons Amicus Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

$63.6 Billion
Q1 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 956,200 shares of FOLD stock, worth $9.49 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

956,200

Previous 77,400 1135.4%

Holding current value

$9.49 Million

Previous $1.1 Million 925.87%

% of portfolio

0.02%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$11.43 - $14.24 $10 Million - $12.5 Million	878,800 Added 1135.4%	956,200 $11.3 Million
Q4 2023 Feb 13, 2024	SELL	$9.97 - $14.52 $707,870 - $1.03 Million	-71,000 Reduced 47.84%	77,400 $1.1 Million
Q3 2023 Nov 14, 2023	BUY	$11.78 - $13.86 $1.75 Million - $2.06 Million	148,400 New	148,400 $1.81 Million
Q1 2023 May 12, 2023	BUY	$10.91 - $13.54 $4.24 Million - $5.27 Million	389,000 New	389,000 $4.31 Million
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $2.8 Million - $3.63 Million	284,800 New	284,800 $2.97 Million

Q1 2020 May 14, 2020	SELL	$6.63 - $11.16 $860,932 - $1.45 Million	-129,854 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$7.48 - $10.75 $10 Million - $14.4 Million	-1,340,946 Reduced 91.17%	129,854 $1.27 Million
Q3 2019 Nov 13, 2019	BUY	$8.02 - $13.25 $9.76 Million - $16.1 Million	1,217,000 Added 479.51%	1,470,800 $11.8 Million
Q2 2019 Aug 12, 2019	BUY	$10.96 - $14.4 $2.78 Million - $3.65 Million	253,800 New	253,800 $3.17 Million

Others Institutions Holding FOLD

# of Institutions

273

Shares Held

325M

Call Options Held

841K

Put Options Held

353K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.78B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account